On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.

ABSTRACT: Cancer is the second leading cause of death affecting nearly one in two people, and the appearance of new cases is projected to rise by >70% by 2030. To effectively combat the menace of cancer, a variety of strategies have been exploited. Among them, the development of peptide-drug conjugates (PDCs) is considered as an inextricable part of this armamentarium and is continuously explored as a viable approach to target malignant tumors. The general architecture of PDCs consists of three building blocks: the tumor-homing peptide, the cytotoxic agent and the biodegradable connecting linker. The aim of the current review is to provide a spherical perspective on the basic principles governing PDCs, as also the methodology to construct them. We aim to offer basic and integral knowledge on the rat

SUBMITTER: Vrettos EI 

PROVIDER: S-EPMC5942387 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature